Click here for Vyndaqel®▼ (tafamidis) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
In February 2020, the European Commission granted marketing authorisation for tafamidis, a transthyretin stabiliser, available as a once-daily 61 mg oral capsule1, for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
Whilst there is a licence for Vyndaqel for ATTR-CM in the UK, there is not currently funded NHS access.
Other available treatment options for ATTR-CM are aimed at symptom management, supportive care including pain management, nutritional and mobility support and mitigation of the effects of the disease on other organs.2
Additional treatment options are currently under investigation. Emerging treatment strategies are aimed at reducing the formation of the amyloid fibrils by targeting different stages of their development.3
Note: These are investigational approaches, and no conclusions can be made about safety and efficacy.
Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.
PP-PFE-GBR-2809. October 2020
Sign up now
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020